QPPV.COM KNOWLEDGE ASSESSMENT

Vilobelimab: Mechanism, EU Authorisation and Pharmacovigilance

Test your understanding of the concepts covered by Vilobelimab: Selective C5a Neutralisation in COVID-19-Associated ARDS.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which follow-up request is most likely to improve assessment of whether a serious event was related to vilobelimab exposure?
Question 2 of 10 Why should comparisons across vilobelimab cases or treatment groups be interpreted cautiously?
Question 3 of 10 Which description best distinguishes vilobelimab's molecular target from that of a medicine that blocks C5 cleavage?
Question 4 of 10 Which statement about spontaneous reports is most accurate for evaluating vilobelimab safety?
Question 5 of 10 A patient develops sepsis after receiving vilobelimab while invasively ventilated and receiving corticosteroids. Which approach best reflects balanced case assessment?
Question 6 of 10 What is the intended functional consequence of selectively neutralising C5a?
Question 7 of 10 For exposure assessment, which time interval is specifically important for the first vilobelimab dose?
Question 8 of 10 A patient deteriorates rapidly, and a serious event is first documented shortly after the first infusion. What should the case reviewer do before interpreting the temporal relationship?
Question 9 of 10 A reviewer is preparing a case chronology. Which sequence of information is most useful for interpreting an infection and subsequent outcome?
Question 10 of 10 Which information set would best support a focused assessment of a suspected infection in a vilobelimab-treated ICU patient?

Select an answer to continue.

QPPV.com